๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Carcinoma of the oral tongue and floor of mouth: Fifteen years' experience with linear accelerator therapy

โœ Scribed by Edward H. Gilbert; Don R. Goffinet; Malcolm A. Bagshaw

Publisher
John Wiley and Sons
Year
1975
Tongue
English
Weight
520 KB
Volume
35
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Radiotherapy after excisional biopsy of
Radiotherapy after excisional biopsy of carcinoma of the oral tongue/floor of the mouth
โœ Dr. William M. Mendenhall; James T. Parsons; Scott P. Stringer; Nicholas J. Cass ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 251 KB

This is an analysis of 16 patients with excisionally biopsied (TXNO) squamous cell carcinoma of the oral tongue (nine patients) and floor of mouth (seven patients) treated with radiotherapy. All patients had a minimum 2-year follow-up and 81% had at least 5 years of follow-up. One patient died of in

Carcinoma of the nasopharynx. Eighteen y
Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy
โœ Richard T. Hoppe; Don R. Goffinet; Malcolm A. Bagshaw ๐Ÿ“‚ Article ๐Ÿ“… 1976 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 561 KB

From 1956 through 1973, 82 patients with carcinoma of the nasopharynx received high dose megavoltage radiation therapy a t Stanford University. The actuarial disease-free (NED) survival was 62% a t 5 years and 56% a t 10 years. The NED survivals a t 5 years for patients with T I , T2, and T3 lesion

Effectiveness of routine follow-up of pa
Effectiveness of routine follow-up of patients treated for T1โ€“2N0 oral squamous cell carcinomas of the floor of mouth and tongue
โœ Matthias Adrianus Wilhelmus Merkx; Joris Jan Martijn van Gulick; Henri August Ma ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 87 KB ๐Ÿ‘ 1 views

## Background: The duration of follow-up after treatment for head and neck cancer, the depth of the routine visits, and the diagnostic tools used are determined on the basis of common acceptance rather than evidence-based practice. patients with early-stage tumors are more likely to benefit from fo